ZERIA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,059 JPY | +0.54% |
|
+2.29% | +2.08% |
| 23/04 | Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints | CI |
| 16/02 | Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3 | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 93,384 | 96,884 | 96,124 | 85,331 | 98,960 | 90,761 | - | - |
| Enterprise Value (EV) 1 | 1,21,122 | 1,23,055 | 1,36,305 | 1,25,855 | 1,32,173 | 1,17,920 | 1,12,691 | 1,07,181 |
| P/E ratio | 27.5 x | 33.3 x | 31.1 x | 21.7 x | 16 x | 11 x | 10.9 x | 9.95 x |
| Yield | 1.78% | 1.63% | 1.62% | 1.84% | 1.78% | 2.19% | 2.33% | 2.48% |
| Capitalization / Revenue | 1.51 x | 1.6 x | 1.73 x | 1.43 x | 1.45 x | 1.21 x | 1.14 x | 1.07 x |
| EV / Revenue | 1.96 x | 2.04 x | 2.46 x | 2.11 x | 1.93 x | 1.57 x | 1.41 x | 1.27 x |
| EV / EBITDA | 16.2 x | 15.3 x | 17.3 x | 10.7 x | 9.15 x | 7.51 x | 6.83 x | 6.3 x |
| EV / FCF | 30.6 x | 32.7 x | -12.9 x | 20.8 x | 12.5 x | 11.5 x | 10.8 x | 9.22 x |
| FCF Yield | 3.27% | 3.06% | -7.75% | 4.81% | 8.01% | 8.69% | 9.29% | 10.8% |
| Price to Book | 1.55 x | 1.84 x | 1.72 x | 1.54 x | 1.51 x | 1.26 x | 1.13 x | 1.05 x |
| Nbr of stocks (in thousands) | 48,816 | 46,400 | 45,708 | 44,817 | 44,080 | 44,080 | - | - |
| Reference price 2 | 1,913 | 2,088 | 2,103 | 1,904 | 2,245 | 2,059 | 2,059 | 2,059 |
| Announcement Date | 10/05/19 | 21/05/20 | 11/05/21 | 11/05/22 | 11/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 61,831 | 60,426 | 55,442 | 59,532 | 68,383 | 75,000 | 79,900 | 84,500 |
| EBITDA 1 | 7,471 | 8,039 | 7,878 | 11,765 | 14,445 | 15,700 | 16,500 | 17,000 |
| EBIT 1 | 3,737 | 4,094 | 3,442 | 6,366 | 9,014 | 9,850 | 10,750 | 11,800 |
| Operating Margin | 6.04% | 6.78% | 6.21% | 10.69% | 13.18% | 13.13% | 13.45% | 13.96% |
| Earnings before Tax (EBT) 1 | 5,221 | 3,920 | 3,922 | 5,721 | 7,272 | 10,520 | 10,780 | 11,885 |
| Net income 1 | 3,454 | 2,925 | 3,119 | 3,961 | 6,195 | 8,250 | 8,300 | 9,125 |
| Net margin | 5.59% | 4.84% | 5.63% | 6.65% | 9.06% | 11% | 10.39% | 10.8% |
| EPS 2 | 69.56 | 62.62 | 67.72 | 87.76 | 140.3 | 187.2 | 188.3 | 207.0 |
| Free Cash Flow 1 | 3,960 | 3,762 | -10,567 | 6,058 | 10,583 | 10,250 | 10,470 | 11,620 |
| FCF margin | 6.4% | 6.23% | -19.06% | 10.18% | 15.48% | 13.67% | 13.1% | 13.75% |
| FCF Conversion (EBITDA) | 53.01% | 46.8% | - | 51.49% | 73.26% | 65.29% | 63.45% | 68.35% |
| FCF Conversion (Net income) | 114.65% | 128.62% | - | 152.94% | 170.83% | 124.24% | 126.14% | 127.34% |
| Dividend per Share 2 | 34.00 | 34.00 | 34.00 | 35.00 | 40.00 | 45.00 | 48.00 | 51.00 |
| Announcement Date | 10/05/19 | 21/05/20 | 11/05/21 | 11/05/22 | 11/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 30,317 | 30,109 | 26,809 | 15,058 | 28,606 | 16,498 | 14,428 | 16,305 | 17,407 | 33,712 | 18,017 | 16,654 | 18,304 | 18,374 | 36,678 | 21,241 | 17,780 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 1,738 | - | 1,388 | 1,421 | 2,672 | 2,823 | 871 | 2,977 | 2,917 | 5,894 | 2,656 | 464 | 2,970 | 2,357 | 5,327 | 4,163 | 509 |
| Operating Margin | 5.73% | - | 5.18% | 9.44% | 9.34% | 17.11% | 6.04% | 18.26% | 16.76% | 17.48% | 14.74% | 2.79% | 16.23% | 12.83% | 14.52% | 19.6% | 2.86% |
| Earnings before Tax (EBT) 1 | 1,627 | - | 1,979 | 1,036 | 3,119 | 2,508 | - | 2,972 | 1,998 | 4,970 | 1,769 | - | 3,355 | 3,057 | 6,412 | 3,783 | 455 |
| Net income 1 | 1,230 | - | 1,218 | 707 | 2,115 | 1,928 | - | 2,601 | 1,397 | 3,998 | 1,982 | 215 | 2,915 | 2,481 | 5,396 | 3,027 | 76 |
| Net margin | 4.06% | - | 4.54% | 4.7% | 7.39% | 11.69% | - | 15.95% | 8.03% | 11.86% | 11% | 1.29% | 15.93% | 13.5% | 14.71% | 14.25% | 0.43% |
| EPS | 26.16 | - | 30.05 | - | 46.65 | 42.68 | - | 58.71 | - | 90.41 | 44.90 | - | 66.14 | - | 122.4 | 68.66 | - |
| Dividend per Share | 17.00 | - | 17.00 | - | 17.00 | - | - | - | - | 18.00 | - | - | - | - | 22.00 | - | - |
| Announcement Date | 01/11/19 | 21/05/20 | 04/11/20 | 04/11/21 | 04/11/21 | 02/02/22 | 11/05/22 | 04/08/22 | 02/11/22 | 02/11/22 | 02/02/23 | 11/05/23 | 03/08/23 | 01/11/23 | 01/11/23 | 01/02/24 | - |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 27,738 | 26,171 | 40,181 | 40,525 | 33,213 | 27,159 | 21,930 | 16,420 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.713 x | 3.255 x | 5.1 x | 3.444 x | 2.299 x | 1.73 x | 1.329 x | 0.9659 x |
| Free Cash Flow 1 | 3,960 | 3,762 | -10,567 | 6,058 | 10,583 | 10,250 | 10,470 | 11,620 |
| ROE (net income / shareholders' equity) | 5.5% | 5.2% | 5.7% | 7.1% | 10.3% | 12.4% | 10.8% | 11% |
| ROA (Net income/ Total Assets) | 2.91% | 3.62% | 2.81% | 4.82% | 5.85% | 7.2% | 6.45% | 6.8% |
| Assets 1 | 1,18,725 | 80,906 | 1,11,014 | 82,137 | 1,05,981 | 1,14,583 | 1,28,682 | 1,34,191 |
| Book Value Per Share 2 | 1,235 | 1,134 | 1,226 | 1,236 | 1,485 | 1,634 | 1,815 | 1,958 |
| Cash Flow per Share | 131.0 | 132.0 | 149.0 | 192.0 | 263.0 | - | - | - |
| Capex 1 | 1,540 | 622 | 14,522 | 1,459 | 3,136 | 3,000 | 4,290 | 4,350 |
| Capex / Sales | 2.49% | 1.03% | 26.19% | 2.45% | 4.59% | 4% | 5.37% | 5.15% |
| Announcement Date | 10/05/19 | 21/05/20 | 11/05/21 | 11/05/22 | 11/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,059
JPY
Average target price
2,810
JPY
Spread / Average Target
+36.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.08% | 577M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 4559 Stock
- Financials Zeria Pharmaceutical Co., Ltd.
